BioCentury | Jan 27, 2017
Targets & Mechanisms

Death metal

...diseases. Stockwell is a professor at Columbia University and co-founder of Kyras Therapeutics Inc. and CombinatoRx...
BioCentury | Sep 29, 2014
Company News

Epirus, Livzon, Joincare deal

...In April, Livzon Mabpharm led Epirus' $36 million series B round. Epirus subsequently reverse-merged with Zalicus Inc....
BioCentury | Sep 26, 2014
Company News

Epirus, Livzon in Asian biosimilar deal

...In April, Livzon led Epirus' $36 million series B round. Epirus subsequently reverse-merged with Zalicus Inc....
BioCentury | Aug 18, 2014
Company News

Horizon Discovery, Otsuka Pharmaceutical deal

...Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line...
...completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx...
...declined to comment on the deal. Horizon acquired its CombinatoRx division earlier this year from Zalicus Inc....
BioCentury | Aug 18, 2014
Company News

Karyopharm management update

...Business: Cancer, Inflammation Hired: Justin Renz as EVP and CFO, formerly EVP and CFO of Zalicus Inc....
BioCentury | Jul 28, 2014
Company News

Epirus, AnaBios deal

...Epirus (formerly Zalicus Inc. ) granted CRO AnaBios exclusive, worldwide rights to develop and commercialize the biotech’s...
...PN3 ; SCN10A ) sodium channels and are in preclinical testing to treat pain. Zalicus...
...sales of products resulting from the license. Earlier this month, Epirus completed a reverse-merger with Zalicus...
BioCentury | Jul 21, 2014
Company News

Zalicus, Epirus deal

...Epirus completed its reverse merger with Zalicus, and the combined company, named Epirus Biopharmaceuticals Inc., began...
...began trading on NASDAQ under the ticker “EPRS” (see BioCentury, April 21 & July 14). Zalicus Inc....
BioCentury | Jul 14, 2014
Company News

Zalicus Inc, Epirus deal

...Zalicus said it and Epirus agreed that Zalicus shareholders will own 19% of the combined company...
...following completion of the companies’ merger. In April, the companies said Epirus would reverse-merge with Zalicus...
...companies have approved the deal, which is subject to approval by shareholders of both companies. Zalicus...
BioCentury | Jun 23, 2014
Product Development

Nav(1.7)igating pain

...candidate in three to four months. Margaret Lee, VP of research and translational medicine at Zalicus Inc....
...penetration per se, but that penetration to particular neurons is important," she said. Last week, Zalicus...
...of products resulting from the license. Zalicus EVP and CFO Justin Renz told BioCentury that Zalicus...
BioCentury | Jun 9, 2014
Company News

Horizon Discovery Group plc, Zalicus Inc. deal

...Horizon completed its acquisition of Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets...
...named Horizon CombinatoRx Inc. (see BioCentury, June 2). Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Zalicus Inc....
Items per page:
1 - 10 of 288
BioCentury | Jan 27, 2017
Targets & Mechanisms

Death metal

...diseases. Stockwell is a professor at Columbia University and co-founder of Kyras Therapeutics Inc. and CombinatoRx...
BioCentury | Sep 29, 2014
Company News

Epirus, Livzon, Joincare deal

...In April, Livzon Mabpharm led Epirus' $36 million series B round. Epirus subsequently reverse-merged with Zalicus Inc....
BioCentury | Sep 26, 2014
Company News

Epirus, Livzon in Asian biosimilar deal

...In April, Livzon led Epirus' $36 million series B round. Epirus subsequently reverse-merged with Zalicus Inc....
BioCentury | Aug 18, 2014
Company News

Horizon Discovery, Otsuka Pharmaceutical deal

...Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line...
...completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx...
...declined to comment on the deal. Horizon acquired its CombinatoRx division earlier this year from Zalicus Inc....
BioCentury | Aug 18, 2014
Company News

Karyopharm management update

...Business: Cancer, Inflammation Hired: Justin Renz as EVP and CFO, formerly EVP and CFO of Zalicus Inc....
BioCentury | Jul 28, 2014
Company News

Epirus, AnaBios deal

...Epirus (formerly Zalicus Inc. ) granted CRO AnaBios exclusive, worldwide rights to develop and commercialize the biotech’s...
...PN3 ; SCN10A ) sodium channels and are in preclinical testing to treat pain. Zalicus...
...sales of products resulting from the license. Earlier this month, Epirus completed a reverse-merger with Zalicus...
BioCentury | Jul 21, 2014
Company News

Zalicus, Epirus deal

...Epirus completed its reverse merger with Zalicus, and the combined company, named Epirus Biopharmaceuticals Inc., began...
...began trading on NASDAQ under the ticker “EPRS” (see BioCentury, April 21 & July 14). Zalicus Inc....
BioCentury | Jul 14, 2014
Company News

Zalicus Inc, Epirus deal

...Zalicus said it and Epirus agreed that Zalicus shareholders will own 19% of the combined company...
...following completion of the companies’ merger. In April, the companies said Epirus would reverse-merge with Zalicus...
...companies have approved the deal, which is subject to approval by shareholders of both companies. Zalicus...
BioCentury | Jun 23, 2014
Product Development

Nav(1.7)igating pain

...candidate in three to four months. Margaret Lee, VP of research and translational medicine at Zalicus Inc....
...penetration per se, but that penetration to particular neurons is important," she said. Last week, Zalicus...
...of products resulting from the license. Zalicus EVP and CFO Justin Renz told BioCentury that Zalicus...
BioCentury | Jun 9, 2014
Company News

Horizon Discovery Group plc, Zalicus Inc. deal

...Horizon completed its acquisition of Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets...
...named Horizon CombinatoRx Inc. (see BioCentury, June 2). Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Zalicus Inc....
Items per page:
1 - 10 of 288